Injectable versus mono-thread PLLA for atrophic acne scars
Poly-L-Lactic Acid: A Comparative Study of Injectable and Thread-Based Delivery in Atrophic Acne Scars
This trial will try two ways of using poly-L-lactic acid—injectable injections versus mono-threads—to improve atrophic acne scars in adults.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 52 (estimated) |
| Ages | 18 Years to 40 Years |
| Sex | All |
| Sponsor | Zagazig University Government |
| Locations | 1 site (Zagazig, Sharqia Province) |
| Trial ID | NCT07523217 on ClinicalTrials.gov |
What this trial studies
In a prospective split-face design, 24 adult patients with Goodman and Baron grade 2–4 atrophic acne scars received PLLA mono-threads on the right side (single session) and injectable PLLA on the left side (two sessions six weeks apart). Clinical outcomes, dermal remodeling, and safety were followed for three months using Goodman and Baron qualitative and quantitative grading systems. The study compares effects on scar appearance, collagen stimulation, and skin physiology between the two delivery modalities. Adverse events and tolerability were monitored for each side.
Who should consider this trial
Good fit: Adults (≥18 years) with clinically diagnosed atrophic acne scars graded 2–4 who can attend Zagazig University Hospital and do not have active acne, recent scar treatment, pregnancy/lactation, bleeding disorders, keloid tendency, systemic wound-healing diseases, or known PLLA allergy are ideal candidates.
Not a fit: Patients with active inflammatory acne, a history of keloids, systemic conditions that impair wound healing, pregnancy or lactation, or known hypersensitivity to PLLA components are unlikely to benefit or be eligible.
Why it matters
Potential benefit: If successful, one delivery method could offer better scar improvement or longer-lasting results with an acceptable safety profile, helping patients and clinicians choose the best option.
How similar studies have performed: Previous studies show PLLA can stimulate neocollagenesis and improve atrophic acne scars, but direct head-to-head comparisons between injectable PLLA and mono-threads are limited.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * included adult patients (≥18 years) of both sexes presenting with clinically diagnosed atrophic acne scars (Grades 2-4 according to the Goodman and Baron classification) Exclusion Criteria: * active acne lesions, pregnancy or lactation, bleeding disorders, keloid tendency, systemic diseases affecting wound healing, recent acne scar treatment within the past six months, and known hypersensitivity to PLLA components.
Where this trial is running
Zagazig, Sharqia Province
- Zagazig University Hospitals — Zagazig, Sharqia Province, Egypt (Recruiting)
Study contacts
- Study coordinator: Reham Essam, MD
- Email: rereessam22@gmail.com
- Phone: +201097709477
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.